Pharmacokinetics of paclitaxel in an anephric patient

Cancer Chemotherapy and Pharmacology

Volumn 43, Issue 1, 1999, Pages 92-96

  Woo, Michael H ^a,b   Gregornik, David ^a,b   Shearer, Patricia D ^d   Meyer, William H ^c   Relling, Mary V ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c Children's Hospital Oklahoma City   (United States)

^d Medical Services International   (Hong Kong)

Author keywords

Hemodialysis; Nifedipine; Paclitaxel; Pharmacokinetics; Renal failure

Indexed keywords

NIFEDIPINE; PACLITAXEL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; FEMALE; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY AGENESIS; KIDNEY FAILURE; NEPHROBLASTOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CHILD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEPHRECTOMY; PACLITAXEL; RENAL DIALYSIS; WILMS TUMOR;

EID: 0032943211     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050868     Document Type: Article

References (24)

1. 1. Brown T, Havlin K, Weiss G, Cagnola J, Koeller J, Kuhn J, Rizzo J, Craig J, Philips J, Von Hoff D (1991) A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 9: 1261
2. 2. Conley BA, Zaharski D, Kearns CM, Rosen DM, Van Echo DA, Egorin MJ (1997) Paclitaxel (P) pharmacokinetic (PK)/ pharmacodynamic (PD) relationships in patients (pts) with renal dysfunction (RD). Proc Annu Meet Am Soc Clin Oncol 16: 233a, abstract 819
3. 3. Cresteil T, Monsarrat B, Alvinerie P, Tréluyer JM, Vieira I, Wright M (1994) Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 54: 386
4. 4. Fazeny B, Olsen SJ, Willey T, Stewart MB, Dittrich E, Huber H, Dittrich C (1995) Pharmacokinetic assessment of paclitaxel in an ovarian cancer patient on hemodialysis. Proc Annu Meet Am Soc Clin Oncol 14: 173 Abstract 375
5. 5. Fedeli L, Colozza M, Boschetti E, Sabalich I, Aristei C, Guerciolini R, Del Favero A, Rossetti R, Tonalo M, Rambotti P, Davis S (1989) Pharmacokinetics of vincristine in cancer patients treated with nifedipine. Cancer 64: 1805
6. 6. Gianni L, Kearns CM, Giani A, Capri G, Viganó L, Locatelli A, Bonadonna G, Egorin M (1995) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/ pharmacodynamic relationships in humans. J Clin Oncol 13: 180
7. 7. Grem JL, Tutsch KD, Simon KJ, Alberti DB, Willson JKV, Tormey DC, Swaminathan S, Trump DL (1987) Phase I study of taxol administered as a short iv infusion daily for 5 days. Cancer Treat Rep 71: 1179
8. 8. Guengerich FP, Brian WR, Iwasaki M, Sari M-A, Bäärnhielm C, Berntsson P (1991) Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J Med Chem 34: 1838
9. 9. Harris JW, Rahman A, Kim B-R, Guengerich FP, Collins JM (1994) Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54: 4026
10. 10. Huizing MT, Keung ACF, Rosing H, van der Kuij V, ten Bokkel Huinink WW, Mandjes IM, Dubbelman AC, Pinedo HM, Beijnen JH (1993) Pharmacokinetics of paclitaxel and metabolites in a randomized cooperative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11: 2127
11. 11. Hurwitz CA, Relling MV, Weitman SD, Ravindranath Y, Vietti TJ, Strother DR, Ragab AH, Pratt CB (1993) Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group study. J Clin Oncol 11: 2324
12. 12. Kumar GN, Walle UK, Walle T (1994) Cytochrome P450 3A-mediated human liver microsomal taxol 6a-hydroxylation. J Pharmacol Exp Ther 268: 1160
13. 13. Longnecker SM, Donehower RC, Cates AE, Chen T-L, Brundrett RB, Grochow LB, Ettinger DS, Colvin M (1987) High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 71: 53
14. 14. Ohtsu T, Sasaki Y, Tamura T, Miyata Y, Nakanomyo H, Nishiwaki Y, Saijo N (1995) Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1: 599
15. 15. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW (1994) Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54: 5543
16. 16. Rowinsky EK, Burke PJ, Karp JE, Tucker RW, Ettinger DS, Donehower RC (1989) Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res 49: 4640
17. 17. Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE, Cornblath DR, Hendricks CB, Donehower RC (1991) Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9: 1692
18. 18. Roy SN, Horwitz SB (1985) A phosphoglycoprotein associated with taxol resistance in J774.2 cells. Cancer Res 45: 3856
19. 19. Schilder LE, Egorin MJ, Zuhowski EG, Rossof AH (1994) The pharmacokinetics of taxol in a dialysis patient. Proc Annu Meet Am Soc Clin Oncol 13: 136, abstract 338
20. 20. Schiller JH, Storer B, Tutsch K, Arzoomanian R, Alberti D, Feierabend C, Spriggs D (1994) Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 12: 241
21. 21. Sonnichsen DS, Hurwitz CA, Pratt CB, Shuster JJ, Relling MV (1994) Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 12: 532
22. 22. Sonnichsen DS, Liu Q. Schuetz EG, Schuetz JD, Pappo A, Relling MV (1995) Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 275: 566
23. 23. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E (1987) Phase I clinical and pharmacokinetic study of taxol. Cancer Res 47: 2486
24. 24. Wiernik PH, Schwartz EL, Einzig A, Strauman JJ. Lipton RB, Dutcher JP (1987) Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 5: 1232